Annual CFO
-$8.49 M
+$234.00 K+2.68%
31 December 2023
Summary:
Biodexa Pharmaceuticals annual cash flow from operations is currently -$8.49 million, with the most recent change of +$234.00 thousand (+2.68%) on 31 December 2023. During the last 3 years, it has risen by +$3.44 million (+28.85%). BDRX annual CFO is now -22.38% below its all-time high of -$6.94 million, reached on 01 December 2013.BDRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BDRX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.7% | - | - |
| 3 y3 years | +28.9% | - | - |
| 5 y5 years | +52.7% | - | - |
BDRX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -2.8% | +28.9% | ||||
| 5 y | 5 years | -2.8% | +52.7% | ||||
| alltime | all time | -22.4% | +55.3% |
Biodexa Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$8.49 M(-2.7%) | - | - |
| Dec 2022 | -$8.73 M(+5.6%) | - | - |
| Dec 2021 | -$8.27 M(-30.8%) | - | - |
| Dec 2020 | -$11.94 M(+44.1%) | - | - |
| Dec 2019 | -$8.29 M(-53.8%) | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$17.95 M(+7.3%) | - | - |
| Dec 2017 | -$16.72 M(-5.7%) | - | - |
| Dec 2016 | -$17.73 M(-6.6%) | - | - |
| Dec 2015 | -$18.98 M(+111.1%) | - | - |
| Dec 2014 | -$8.99 M(+29.6%) | - | - |
| Dec 2013 | -$6.94 M | - | - |
FAQ
- What is Biodexa Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Biodexa Pharmaceuticals?
- What is Biodexa Pharmaceuticals annual CFO year-on-year change?
What is Biodexa Pharmaceuticals annual cash flow from operations?
The current annual CFO of BDRX is -$8.49 M
What is the all time high annual CFO for Biodexa Pharmaceuticals?
Biodexa Pharmaceuticals all-time high annual cash flow from operations is -$6.94 M
What is Biodexa Pharmaceuticals annual CFO year-on-year change?
Over the past year, BDRX annual cash flow from operations has changed by +$234.00 K (+2.68%)